Mobia Medical (NASDAQ:MOBI) Director Casey Tansey Buys 16,441 Shares of Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 16,441 shares of Mobia Medical stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $12.07 per share, with a total value of $198,442.87. Following the completion of the purchase, the director owned 318,332 shares in the company, valued at approximately $3,842,267.24. This represents a 5.45% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mobia Medical Trading Down 4.1%

Shares of NASDAQ MOBI opened at $10.95 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80. Mobia Medical, Inc. has a one year low of $10.19 and a one year high of $15.29. The business’s 50-day simple moving average is $12.35. The firm has a market cap of $364.54 million and a price-to-earnings ratio of -0.54.

Mobia Medical (NASDAQ:MOBI) last issued its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. The firm’s revenue for the quarter was up 102.4% on a year-over-year basis. Research analysts anticipate that Mobia Medical, Inc. will post -2.76 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. The Goldman Sachs Group started coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $31.00 price objective on the stock. BTIG Research reissued a “buy” rating and set a $19.00 target price on shares of Mobia Medical in a research note on Wednesday, August 12th. JPMorgan Chase & Co. boosted their price target on shares of Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Weiss Ratings began coverage on shares of Mobia Medical in a research note on Wednesday, August 12th. They issued a “sell (e-)” rating on the stock. Finally, Bank of America began coverage on Mobia Medical in a report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.